Further research will be directed at the synthetic lethal interaction of RB loss with Skp2 overexpression in castration-resistant prostate cancer and targeting of Skp2 by combination of Bortezomib and FKB or its derivatives for treatment of RB deficient, castration resistant prostate cancer. The gene discussed is SKP2; the disease is prostate carcinoma.